Promising drug targets rare chest cancers in new trial

NCT ID NCT06248515

Recruiting now Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called sacituzumab govitecan in adults with advanced thymoma or thymic carcinoma that has worsened after at least one prior treatment. The main goal is to see how many patients' tumors shrink or disappear. Participants receive the drug intravenously weekly for two weeks, then a week off, and are monitored with blood tests and scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED THYMOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

invasive malignant thymoma thymic carcinoma thymoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYMIC CARCINOMA THYMOMA

Contacts and locations

Locations

John Theurer Cancer Center at Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
Lombardi Comprehensive Cancer Center, Georgetown University
RECRUITING

Washington D.C., District of Columbia, 20007, United States
Stanford Cancer Institute
RECRUITING

Palo Alto, California, 94304, United States
University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.